Phase 3 Clinical Trials With Primary Completion Dates in June 2026
This is a list of Phase 3 trials with primary completion dates in June 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ARDX | Ardelyx, Inc. | 2026-06-01 | Phase 3 | NCT05643534 | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
| BVNRY | Bavarian Nordic A/S | 2026-06-01 | Phase 3 | NCT06844500 | Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC |
| BZYR | Burzynski Research Institute, Inc. | 2026-06-01 | Phase 3 | NCT02887040 | Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma |
| CGON | CG Oncology, Inc. | 2026-06-01 | Phase 3 | NCT06111235 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT |
| GNLX | Genelux Corporation | 2026-06-01 | Phase 3 | NCT05281471 | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) |
| PRAX | Praxis Precision Medicines, Inc. | 2026-06-01 | Phase 3 | NCT07019922 | A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety |
| RCUS | Arcus Biosciences, Inc. | 2026-06-01 | Phase 3 | NCT05568095 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body |
| REGMF | RemeGen Co., Ltd. | 2026-06-01 | Phase 3 | NCT05885503 | Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema |
| REGMF | RemeGen Co., Ltd. | 2026-06-01 | Phase 3 | NCT05799287 | A Study of Telitacicept for IgA Nephropathy (TELIGAN) |
| RNXT | RenovoRx, Inc. | 2026-06-01 | Phase 3 | NCT03257033 | Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC |
| SNPHY | Santen Pharmaceutical Co., Ltd. | 2026-06-01 | Phase 3 | NCT06683651 | A Study in Chinese Patients With Acquired Blepharoptosis |
| TLX | Telix Pharmaceuticals Limited | 2026-06-01 | Phase 3 | NCT07052214 | PSMA PET Combined With MRI for the Detection of PCa |
| VNDA | Vanda Pharmaceuticals Inc. | 2026-06-01 | Phase 3 | NCT04652882 | Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) |